CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
Dupilumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03667014
NCT03667014Phase 4Completed
CompareCT.gov

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

University of California, San Francisco·interventional·Posted Sep 12, 2018·Updated Jan 9, 2024

In Brief

A Phase 4 clinical trial evaluating Dupilumab for Atopic Dermatitis and Atopic Dermatitis Eczema. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Atopic Dermatitis Eczema
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 12, 2018
Enrollment StartNov 1, 2018
Primary CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.8 years ago

Interventions

Dupilumabdrug

Dupilumab treatment